U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07832227) titled 'Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial' on Sept. 14.
Brief Summary: This is a phase 2, interventional treatment trial evaluating imlunestrant, abemaciclib, and selinexor in two separate patient cohorts: low grade serous ovarian cancer and endometrioid endometrial cancer. The study is non-randomized and open-label. Treatment is administered in the outpatient setting, with a 14-day Cycle 0 followed by 28-day treatment cycles.
Study Start Date: Dec. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Low Grade Ovarian Serous Adenocarcinoma
Endometrial Cancer
Intervention:
DRUG: Imlunestrant
Oral study drug Tak...